P14.15 Benefit of Bevacizumab for recurrent glioblastoma. Results of 81 patients from a single institution

BACKGROUND: No standard of care has been established for patients with progressive glioblastoma (rGBM). Previous studies suggested that bevacizumab (BEV) is safe and produces responses that result in a decreased use of glucocorticoids and increased progression-free survival (PFS) with an unclear eff...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Absalyamova, O, Kobiakov, G, Agabekyan, G, Poddubsky, A, Belyashova, A, Lodygina, K, Absalyamov, A, Kobiakov, N
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Poster Presentations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795927/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.250
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia